Why Pfizer's Post-COVID Future Looks Brighter Than Ever

Pfizer is experiencing a significant decline in COVID-19 product sales, with Comirnaty revenue collapsing from a 2021 peak of $36.8 billion. However, the company has strategically reinvested its COVID-era profits, notably through the $43 billion Seagen acquisition in 2023, to build a robust oncology pipeline. This pivot is now driving future growth, with cancer treatments like Padcev seeing 38% Q2 sales growth to an annualized $2.2 billion and Elrexfio demonstrating potential for over $5 billion in peak annual sales, effectively offsetting the previous revenue downturn.

Analysis

Pfizer is navigating a significant strategic pivot away from its collapsed COVID-19 franchise, a transition underscored by a 61% stock price decline from its late 2021 peak. Revenue from its COVID-19 vaccine, Comirnaty, has plummeted from $36.8 billion in 2021 to just $945 million in the first half of 2025, while sales of the antiviral Paxlovid fell 60% year-over-year to $918 million. In response, the company has redeployed capital, most notably through the $43 billion acquisition of Seagen in 2023, to build a formidable oncology pipeline that is now beginning to drive growth. A key asset, the bladder cancer treatment Padcev, saw sales jump 38% year-over-year in the second quarter to an annualized $2.2 billion, with potential for further expansion following positive results in an adjuvant setting trial. Another promising drug, Elrexfio, approved for multiple myeloma, has demonstrated a 97% tumor shrinkage rate in newly diagnosed patients, suggesting its potential for peak annual sales to exceed $5 billion as it moves into earlier treatment lines. This shift indicates that Pfizer's future growth trajectory is now heavily dependent on the successful commercialization and label expansion of these newly acquired cancer therapies.

Key Decisions for Investors

• Investors should look past the headline decline in COVID-19 product revenue and evaluate Pfizer based on the performance of its oncology portfolio, particularly the assets acquired from Seagen.
• Monitor upcoming clinical trial data and regulatory approvals for Padcev in the adjuvant setting and Elrexfio in earlier lines of multiple myeloma treatment, as these are primary drivers for achieving multi-billion dollar peak sales projections.
• Given the stock's significant 61% decline from its 2021 peak, the current valuation may present an attractive entry point for long-term investors confident in the execution of the company's pivot to oncology.